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Abstract
There is a widespread agreement from patient and professional
organisations alike that the safety of stem cell therapeutics is of
paramount importance, particularly for ex vivo autologous gene
therapy. Yet current technology makes it difficult to thoroughly
evaluate the behaviour of genetically corrected stem cells before
they are transplanted. To address this, we have developed a strat-
egy that permits transplantation of a clonal population of geneti-
cally corrected autologous stem cells that meet stringent
selection criteria and the principle of precaution. As a proof of
concept, we have stably transduced epidermal stem cells (holo-
clones) obtained from a patient suffering from recessive dystro-
phic epidermolysis bullosa. Holoclones were infected with self-
inactivating retroviruses bearing a COL7A1 cDNA and cloned
before the progeny of individual stem cells were characterised
using a number of criteria. Clonal analysis revealed a great deal
of heterogeneity among transduced stem cells in their capacity to
produce functional type VII collagen (COLVII). Selected transduced
stem cells transplanted onto immunodeficient mice regenerated a
non-blistering epidermis for months and produced a functional
COLVII. Safety was assessed by determining the sites of proviral
integration, rearrangements and hit genes and by whole-genome
sequencing. The progeny of the selected stem cells also had a
diploid karyotype, was not tumorigenic and did not disseminate
after long-term transplantation onto immunodeficient mice. In
conclusion, a clonal strategy is a powerful and efficient means of
by-passing the heterogeneity of a transduced stem cell popula-
tion. It guarantees a safe and homogenous medicinal product,
fulfilling the principle of precaution and the requirements of
regulatory affairs. Furthermore, a clonal strategy makes it possi-
ble to envision exciting gene-editing technologies like zinc finger
nucleases, TALENs and homologous recombination for next-
generation gene therapy.
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Introduction
Ex vivo gene therapy can permanently cure debilitating hereditary
diseases (Hacein-Bey-Abina et al, 2002; Mavilio et al, 2006; Ott
et al, 2006; Gargioli et al, 2008; Naldini, 2009; Mavilio, 2010; Tedesco
et al, 2011; Aiuti et al, 2013; Biffi et al, 2013). Therapeutical success
has been obtained in pioneer trials using genetically corrected
human bone marrow stem cells to treat patients suffering from
X-linked severe combined immunodeficiency (SCID) (Hacein-Bey-
Abina et al, 2002), X-linked adrenoleukodystrophy (ALD) (Cartier
et al, 2009) and SCID-adenosine deaminase (ADA-SCID) (Aiuti et al,
2009). However, unexpected complications like T-cell leukaemia
have raised concerns (Hacein-Bey-Abina et al, 2003; Howe et al,
2008) about the safety of ex vivo gene therapy (Williams & Baum,
2003). Complications result from insertional mutagenesis together
with clonal dominance (Hacein-Bey-Abina et al, 2008; Howe et al,
2008). Hence, the population of recombinant stem cells should be
characterised before it is transplanted (Halme & Kessler, 2006; Fink,
2009). However, most tissue stem cells (e.g. hematopoietic and
neural stem cells) cannot be efficiently expanded in culture by
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present technologies. To compensate for this limitation, integration
sites have been documented in engrafted cells but it is only
informative a posteriori (Aiuti et al, 2013).
Human epidermal stem cells are privileged among adult (tissue)
stem cells because they can be efficiently expanded ex vivo (Gallico
et al, 1984; Rochat et al, 2013). The technology is based on the use
of a lethally irradiated feeder layer of mouse 3T3-J2 cells that
provides the necessary microenvironment to promote stem cell
expansion (Rheinwald & Green, 1975; Barrandon & Green, 1987;
Barrandon et al, 2012). Using this technology, it is possible to
isolate enough epidermal stem cells from a small skin biopsy to
generate large amounts of keratinocytes when cells are properly
cultured; our laboratory is routinely using a strain of human diploid
keratinocytes (YF29) isolated more than 25 years ago from the fore-
skin of a newborn. Most importantly, epidermal stem cells are used
worldwide to treat extensive third-degree burn wounds to perma-
nently restore epidermis (Gallico et al, 1984; Pellegrini et al, 1999;
Ronfard et al, 2000; Chua et al, 2008; Cirodde et al, 2011). The use
of autologous cultured epithelium is approved by FDA (Food and
Drug Administration) as a humanitarian use device and is commer-
cially available worldwide. Moreover, it is possible to efficiently
clone epidermal stem cells and to obtain a large progeny from a
single stem cell, a property that we have used to characterise growth
capabilities and transplantability (Barrandon & Green, 1987; Rochat
et al, 1994; Mathor et al, 1996; Claudinot et al, 2005; Majo et al,
2008; Bonfanti et al, 2010). Furthermore, human epidermal stem
cells can be efficiently transduced by means of recombinant retrovi-
ruses to produce proteins of medical interest (Morgan et al, 1987;
Mathor et al, 1996; Warrick et al, 2012). This was used to trans-
plant a patient suffering from junctional epidermolysis bullosa with
an engineered recombinant cultured epidermis producing laminin 5
(Mavilio et al, 2006; De Rosa et al, 2014). Taken together, these
observations lead us to consider the feasibility of a single stem cell
strategy for ex vivo gene therapy of debilitating hereditary skin
disease while assessing its medical safety before clinical use.
To demonstrate the feasibility of our strategy, we have selected
severe generalised recessive dystrophic epidermolysis bullosa
(Hallopeau-Siemens RDEB, OMIM 226600) as a model system for
the following reasons. First, RDEB is a genodermatosis for which
there is no curative treatment. RDEB is characterised by an extre-
mely severe blistering due to poor adherence of epidermis to the
dermis caused by deficient type VII collagen (COLVII), the major
component of the anchoring fibrils (Bruckner-Tuderman et al, 1999;
Fine et al, 2008). As a consequence, RDEB patients have extensive
chronic wounds that can ultimately lead to death by invasive
squamous cell carcinomas (Fine et al, 2009). Second, the severity of
the disease has led to major therapeutic adventures like the trans-
plantation of allogeneic bone marrow stem cells (Wagner et al,
2010), resulting in several patients’ death (Tolar & Wagner, 2012,
2013) and other unconventional therapeutic alternatives (Woodley
et al, 2007; Wong et al, 2008; Remington et al, 2009; Siprashvili
et al, 2010; Itoh et al, 2011; Tolar et al, 2011). Third, we have
demonstrated that a clone of human keratinocytes can produce
COLVII and participate in the formation of anchoring fibrils (Regauer
et al, 1990). Fourth, we have access to patients with well-characterised
mutations, and among them a patient with a homozygous inser-
tion–deletion resulting in a premature stop codon and absence of
functional COLVII (Hilal et al, 1993; Hovnanian et al, 1997).
Our strategy is inspired by the protocols and guidelines
developed by the biotechnology industry and regulatory affairs to
produce medicinal proteins by means of genetically engineered
mammalian cells [http://www.ich.org/fileadmin/Public_Web_Site/
ICH_Products/Guidelines/Quality/Q5D/Step4/Q5D_Guideline.pdf
(ICH, 1997); http://www.ich.org/fileadmin/Public_Web_Site/ICH_
Products/Guidelines/Quality/Q7/Step4/Q7_Guideline.pdf (ICH, 2000);
Figure 1. Strategy toperformexvivogenetherapy fromasingleepidermal
stem cell.
Schematic strategy to produce a performant and safe gene therapy product from a
single autologous epidermal stem cell. (1) A biopsy is obtained from the patient to
isolate epidermal stem cells that are then expanded under appropriate conditions
(2). An aliquot of the culture is infected with the ad hoc recombinant shuttle virus
(3). Single cells are then isolated (4) and clones expanded to built a frozen stem cell
bank (5). In parallel, an aliquot of each clone is expanded to select for a clone
fulfilling the criteria described in Table 1. After validation (6), the approved clone is
thawed and expanded to createmaster andworking cell banks in a GMP facility (7).
Genetically modified CEA are then produced (8) and grafts are transplanted onto
the patient (9). MCB, master cell bank; WCB, working cell bank; CEA, cultured
epidermal autografts; GLP, good laboratory practice; GMP, good manufacturing
practice; GCP, good clinical practice.
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http://www.isscr.org/docs/guidelines/isscrglclinicaltrans.pdf (ISSCR,
2008)]. The best clone following GLP (good laboratory practices)
is first fully characterised and then transferred to GMP (good
manufacturing practices) to prepare the master and working cell
banks. The strategy for ex vivo gene therapy (Fig 1) is firstly
isolation of epidermal stem cells from a patient’s biopsy (step 1)
and cultivation (step 2) before being permanently transduced by
means of disease-specific viral shuttle vectors (step 3). Single
cells are then isolated to obtain clones (step 4) that are
expanded before they are individually frozen (step 5). In parallel,
a small aliquot of each clone is expanded for further characteri-
sation and validation (step 6). Once a clone fulfils the strict
functionality and safety requirements described in Table 1,
master and working cell banks are prepared in a GMP facility
(step 7) in which genetically corrected autologous cultured
epithelia (CEA) are also produced (step 8). These CEA are then
transferred to the clinic and transplanted onto the patient (step
9). Our experiments have demonstrated that it is possible to
produce enough genetically corrected autologous transplants
from a single human epidermal stem cell for a pilot clinical trial
fulfilling strict safety criteria.
Results
Identification of epidermal stem cells in the skin of an
RDEB patient
Recessive dystrophic epidermolysis bullosa keratinocytes were
isolated from a small skin biopsy obtained from a 4-year-old patient
with a homozygous insertion–deletion in the type VII collagen gene
(COL7A1) leading to a premature stop codon in the fibronectin 5
domain and to the formation of severely truncated type VII collagen
(Hilal et al, 1993). RDEB clonogenic keratinocytes were cultivated
onto lethally irradiated 3T3-J2 cells according to standard procedures
used for cell therapy of third-degree burn wounds (Pellegrini
et al, 1999; Ronfard et al, 2000). No COLVII was detected in skin
biopsies, nor in cultured fibroblasts and keratinocytes (Supplemen-
tary Fig S1). Because RDEB keratinocytes have been described as
poor growers in the literature (Morley et al, 2003), we first deter-
mined the lifespan of RDEB clonogenic keratinocytes obtained from
an early passage. Cells were subcultured once a week for 5 months
(Fig 2A), and the percentage of growing colonies determined as it is
the most reliable indicator of the growth capacity of a keratinocyte
culture (Rochat et al, 2013). As expected, colony-forming efficiency
(CFE) and the number of growing colonies decreased with time but
at a similar rate to that of healthy keratinocytes, demonstrating that
the growth potential of RDEB cells was not different from that of
healthy cells of similar age. To further analyse the growth potential
of RDEB clonogenic keratinocytes, we cloned individual RDEB
keratinocytes that had already undergone five subcultures and at
least 30 doublings (patient cells divided on average once a day)
(Barrandon & Green, 1987). This experiment demonstrated the pres-
ence of holoclones (6% of clones) (Fig 2B), considered as the
phenotype of human keratinocyte stem cells in culture (Barrandon
& Green, 1987; Mathor et al, 1996; Rama et al, 2010; Rochat et al,
2013). Our data demonstrate that RDEB keratinocyte stem cells can
be expanded in culture and cloned as are healthy keratinocytes.
Genetic correction of RDEB epidermal stem cells
RDEB keratinocytes were infected as a passage IV mass culture with
a suspension of self-inactivating (SIN) retroviruses bearing a
COL7A1 cDNA under the control of a minimal human elongation
factor 1a (EF1a) promoter (Supplementary Fig S2) as previously
described (Titeux et al, 2010). We first demonstrated that the infec-
tion procedure was compatible with stem cell maintenance (Supple-
mentary Fig S3) and that on average thirty-five to forty-two per cent
of the infected RDEB keratinocytes were positive for COLVII by
immunostaining (Supplementary Fig S4). Next, we manually
Table 1. Selection criteria for safety assessments of medicinal epidermal stem cells.
Selection criteria Assays
Levels of confidence
Mass culture Clonal culture
Quality of medicinal
product
High growth potential Clonal analysis Low High
Production of the protein of interest Western blotting/Immunocytochemistry Low High
Long-term tissue regeneration In vivo transplantation onto immunodeficient mice Low High
Long-term correction of the disease In vivo transplantation onto immunodeficient mice Low High
Safety of medicinal
product
No immortalisation Serial passaging (cellular lifespan) Low High
Western blotting (G1 checkpoint) Low High
Karyotyping Low High
No tumorigenic potential Subcutaneous injection into athymic mice Low High
Determination of proviral
integrations
Ligation-mediated PCR Low Medium
Fluorescence in situ hybridisation Low High
Whole-genome sequencing Low High
No dissemination of genetically
modified human stem cells
Organ analysis of transplanted immunodeficient mice Low High
Selection criteria used to determine efficacy and safety of corrected stem cells before transplantation. These could be performed on mass culture or on single cell
expansion. We determined the degree of reliability of each assay as low, medium and high. A clonal strategy gives a higher level of safety.
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isolated one hundred and fifty single cells with a Pasteur pipette
under an inverted microscope (Barrandon & Green, 1985). Sixty-
seven clones were obtained, fifteen of which were obviously
non-growing (paraclones). Each of the remaining fifty-two clones
was transferred individually in several Petri dishes, first to expand
the population, second to determine the clonal type (Barrandon &
Green, 1987) and third to determine the production of COLVII.
Three clones were classified as holoclones, forty-two as meroclones
and three as paraclones; four clones were lost during cultivation for
technical problems (Supplementary Table S1). COLVII was immuno-
detected in two holoclones (out of three), eighteen meroclones (out
of forty-two) and three paraclones (all positive) (Supplementary
Table S1). This demonstrated that keratinocytes with extensive or
restricted growth potential were equally transduced and that COLVII
expression was independent of clonal type. Next, we thoroughly
characterised COLVII-positive clones (cl.6, cl.17, cl.22, cl.58 and
cl.61) and COLVII-negative clones (cl.3, cl.24 and cl.54) (Fig 3A).
qPCR experiments confirmed that the expression of COL7A1 was
variable in different clones (Fig 3B), with levels of mRNAs varying
from twofold to fiftyfold (clone 3 and clone 58, respectively)
compared to uninfected RDEB keratinocytes. As expected, the life-
span of the individual clones was different, holoclones having a
higher growth potential than meroclones (Supplementary Fig S5).
We then showed that transduced keratinocytes expressed COLVII
until the last subculture, eleven weeks after the start of the experi-
ment (Supplementary Fig S6). Transduced COL7A1 cDNAs are known
to frequently rearrange in contrast to other collagens (F. Mavilio,
unpublished data); therefore, we performed Southern blots on
genomic DNA obtained from several transduced clones using a
COL7A1-specific probe (Fig 3C). The retroviral producer cloned line
Flp293A-E1aColVII1 was used as a positive control. Bands corre-
sponding to endogenous COL7A1 (16 kb) and proviral DNA
(9.6 kb) were observed in control cells, whereas bands correspond-
ing to the expected proviral DNA and rearranged proviral DNA were
observed in clones 6 and 54. These rearrangements were not clearly
detected in the infected cell pools from which clones 6 and 54 were
isolated (lane 3); this does not mean that there was no rearrange-
ment in the mass culture containing thousands of transduced stem
cells, but rather that the use of a genetically homogenous population
(clones) increased the threshold of detection. Next, the culture
supernatants of transduced keratinocytes were analysed to deter-
mine whether COLVII was secreted. Only clone 6 correctly secreted
COLVII while clone 54 did not (Fig 3D), further emphasising that a
mass culture of transduced cells is vastly heterogeneous. This
observation by itself justifies the clonal strategy.
RDEB-corrected stem cells generate a functional
self-renewing epidermis
The first selection criterion for suitable gene therapy is the high
growth potential of the COLVII-producing cells (corrected stem
cells). This is a sine qua non condition to obtain a sufficient
number of recombinant grafts to treat a patient. We thus
performed serial transfer analysis of corrected clone 6 and
compared it to COLVII non-producing clone 54 (uncorrected)
(Fig 4A). Clones 6 and 54 had an extended lifespan as expected
from their clonal type. Clone 6 could undergo eleven serial trans-
fers from the day of cloning, which equals to fifty-nine population
doublings, yielding a theoretical progeny of up to 5.7 × 1017 cells
(Fig 4B). Collectively, these experiments demonstrated that a single
transduced stem cell (holoclone) could generate a progeny large
enough to produce medicinal CEA to treat wide areas of diseased
skin.
Genetically corrected keratinocytes obtained from a single trans-
duced stem cell were challenged in a long-term transplantation
assay to determine whether they could regenerate a functional
epidermis. Cells were plated onto a fibrin-based matrix containing
autologous untransduced RDEB fibroblasts and were grown to
confluence, and engineered epithelia were transplanted onto immu-
nodeficient SCID mice (Larcher et al, 2007). Biopsies of the engrafted
area were then performed at various time points and processed
for histology to confirm the human origin of the epidermis (HLA-1
A B
Figure 2. Extensive growth potential of recessive dystrophic epidermolysis bullosa (RDEB) epidermal keratinocytes.
A Keratinocytes were isolated from the skin of a 4-year-old patient with severe-generalised RDEB linked to homozygous insertion–deletion in COL7A1 (Hilal et al, 1993).
Cultured RDEB cells (blue line) were serially passaged for more than 4 months, displaying a growth potential similar to non-diseased control cells (YF29) isolated from
the foreskin of a newborn (black line). To calculate the percentage of growing colonies, 100 to 1,000 cells were plated into indicator dishes at each passage. Cells
were grown for 12 days, fixed and stained with rhodamine B. Colonies were scored as growing or aborted (Barrandon & Green, 1987).
B Clonal analysis demonstrated the presence of stem cells (holoclones) in a passage VII RDEB culture (95% of growing colonies).
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positive) and for immunodetection of COLVII (Fig 4). Untransduced
RDEB keratinocytes generated a normal epidermis, which was blis-
tering and poorly attached onto the underlying dermis, consistent
with an absence of COLVII (Fig 4C). COL7A1 transduced clone 22,
which did not secrete COLVII (Fig 3D), generated an epidermis that
behaved like untransduced RDEB keratinocytes. On the other hand,
corrected clone 6 formed a normal epidermis that adhered to the
underlying dermis and did not blister for at least 385 days, time at
A
B C
D
Figure 3. Isolation of genetically corrected recessive dystrophic epidermolysis bullosa (RDEB) epidermal stem cells.
Single cells were isolated from a mass culture (passage V) of RDEB keratinocytes infected with SIN retroviruses bearing a COL7A1 cDNA. Clonal types were determined
(Barrandon & Green, 1987) and listed in Supplementary Table S1. Growing clones were expanded for further characterisation.
A COLVII detection in clones by immunostaining. COLVII expression (green) was detectable in some clones (6, 17, 22, 58 and 61) and not in others (3, 24 and 54); nuclei
were stained with Hoechst 33342 (blue). Dotted lines delimit the periphery of keratinocyte colonies from the surrounding irradiated 3T3-J2 feeder cells. Scale bar:
50 lm.
B Quantitative RT–PCR analysis of COL7A1 expression in transduced clones compared to untransduced RDEB keratinocytes. All clones shown in (A) were transduced but
expressed different levels of COL7A1 transcripts. Clones 6, 17, 22, 54, 58 and 61 expressed higher levels of COL7A1 than control RDEB cells and keratinocytes obtained
from healthy donors (YF29 and OR-CA, control 1 and 2, respectively). The level of COL7A1 expression in the RDEB untransduced cells was referenced as 1.
C Determination of proviral rearrangements in transduced clones. A Southern blot was performed using genomic DNA of RDEB cells, clones and the infected mass culture
from which the clones were isolated. Genomic DNA was digested with EcoRV and SpeI that cut at the 30 and 50 end of the provirus (Supplementary Fig S2) and
hybridised with a 907-bp COL7A1 probe radiolabelled with 32P isotope. The upper band corresponded to the endogenous signal. The retroviral producer line
Flp293A-E1aColVII1 was used as a control for the digested 9.6-kb provirus (proviral signal). Smaller bands corresponded to rearranged proviruses marked with an asterisk.
D Identification of stem cells producing COLVII. Western blotting revealed that only clone 6 secreted COLVII in the culture supernatant, while clone 54 and surprisingly
clone 22 did not (see A). RDEB cells were used as a negative control and healthy donor cells as a positive control. The secreted matrix metalloproteinase 2 (MMP2)
was used as a loading control.
EMBO Molecular Medicine Vol 7 | No 4 | 2015 ª 2015 The Authors
EMBO Molecular Medicine Single stem cell for safe gene therapy Stéphanie Droz-Georget Lathion et al
384
Published online: February 27, 2015 
which the experiment was terminated because of the age of
recipient mice. Proliferative KI67-positive keratinocytes were
detected in the basal cell layer of the regenerated epidermis, indicat-
ing self-renewal and COLVII deposition were observed at the dermo-
epidermal junction in biopsies taken at various time during the
experiment (Fig 4C). Electron microscopy was used to determine
whether the COLVII produced by the corrected RDEB keratinocytes
could participate in the formation of anchoring fibrils. Numerous
anchoring fibrils containing human COLVII were observed at the
basement membrane by immunogold staining (Fig 4D), whereas no
anchoring fibrils were observed in RDEB transplants. Collectively,
these experiments demonstrate that the progeny of a genetically
corrected stem cell is capable of generating a self-renewing COLVII-
producing epidermis for more than a year, demonstrating the feasi-
bility of a single stem cell strategy for ex vivo gene therapy.
Safety assessment of RDEB-corrected stem cells
On the basis of the scientific literature (Fink, 2009; Taylor et al,
2010; Goldring et al, 2011; Daley, 2012; Scadden & Srivastava, 2012)
A B
C
D
Figure 4. Long-term restoration of COLVII expression, generation of epidermis and anchoring fibrils by the progeny of a corrected recessive dystrophic
epidermolysis bullosa (RDEB) epidermal stem cell.
A Serial cultivation of transduced and untransduced holoclones demonstrated that the growth potential of the stem cells was not affected by the production of COLVII.
Non-COLVII-producing holoclone 54 (black lines) and COLVII-producing holoclone 6 (red lines) were serially transferred once a week until exhaustion (Rochat et al,
1994).
B Theoretical number of epidermal cells available for characterisation and CEA production from corrected (clone 6) and uncorrected stem cells (clone 54) calculated
from the day of cloning. The colony-forming efficiency and the percentage of growing colonies for each passage were used to calculate the population doubling, the
generation number and the total progeny of isolated stem cells. Both corrected and uncorrected epidermal stem cells show high growth potential in vitro.
C Immunodeficient SCID mice were transplanted with untransduced cultured RDEB keratinocytes (left) or the COLVII-secreting holoclone (clone 6) (right). Punch
biopsies were obtained at various times post-transplantation (PT), stained with haematoxylin/eosine (H/E), for human leucocyte antigen-1 (HLA-1) (green) and human
COLVII (red). RDEB keratinocytes generated a HLA-1-positive epidermis that adhered poorly to the dermo-epidermal junction (DEJ) (arrow indicates a blister) and
absence of COLVII (dotted line delimits the dermis), whereas the corrected keratinocytes produced an epidermis that adhered to the dermis and deposited COLVII
(red) at the DEJ. Note the presence of KI67-positive keratinocytes (red) in the basal and suprabasal layers in the corrected epidermis at 385 days post-transplantation,
indicating that transplanted cells had self-renewed for more than a year. Scale bar: 50 lm.
D Transmission electron microscopy (TEM) demonstrated the presence of anchoring fibrils (arrows) at the DEJ of the corrected epidermis (middle right panel) and in a
normal human skin biopsy (left panel). Note the absence of anchoring fibrils in the RDEB epidermis (middle left panel). Detection of human COLVII by immunogold
staining in the DEJ of corrected epidermis (right panel). Scale bar: 250 nm.
ª 2015 The Authors EMBO Molecular Medicine Vol 7 | No 4 | 2015
Stéphanie Droz-Georget Lathion et al Single stem cell for safe gene therapy EMBO Molecular Medicine
385
Published online: February 27, 2015 
and regulatory affair guidelines [http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM
070273.pdf (FDA, 2008); http://www.isscr.org/docs/guidelines/
isscrglclinicaltrans.pdf (ISSCR, 2008)], we anticipated that the
progeny of a genetically corrected stem cell should meet a number
of safety criteria (Table 1). Accordingly, clones selected at the initial
phase of the experimental protocol were put through a battery of
tests. First, we determined the number and sites of proviral integra-
tions by ligation-mediated PCR (LM-PCR) on transduced clones 6,
22 and 54. To perform LM-PCR, transduced keratinocytes were
subcultured twice in the absence of feeder cells. Two integrations
were found in transduced clone 6 and in clone 54 (Supplementary
Table S2). Proviruses were inserted in the first intron or in the
promoter region of hit genes as previously observed (Montini et al,
2006; Cattoglio et al, 2010). No clear data were obtained by LM-PCR
for clone 22 due to remaining contamination with murine sequences
from the feeder layer. To confirm this, we analysed clone 6 by
fluorescence in situ hybridisation (FISH) but not clone 54 since it
did not produce COLVII. FISH analysis demonstrated a specific
hybridisation of COL7A1 cDNA on five chromosomes, one signal on
each chromosome 3, corresponding to endogenous COL7A1, one
signal on a chromosome 2, one on a chromosome 22, confirming
the LM-PCR results, and revealed an additional signal on a chromo-
some 11 (Fig 5A). We then investigated the integration sites by
whole-genome sequencing. Next-generation sequencing (NGS) data
analyses confirmed FISH results and permitted to estimate the loca-
tion of the three proviral integrations (chromosomes 2, 22 and 11)
(Fig 5B). Raw data are accessible on http://ncbi.nlm.nih.gov/sra/
accession number SRP050326. Integration sites were then individu-
ally characterised by conventional sequencing with a definition at a
base-pair level (Fig 5B). Sequencing data confirmed the integrations
identified by LM-PCR on chromosomes 2 and 22 and confirmed the
integration on chromosome 11 discovered by FISH. Most impor-
tantly, these experiments demonstrated that the proviruses did not
integrate in or in the vicinity of known oncogenes, therefore dimin-
ishing or even alleviating the risk of uncontrolled cell proliferation.
One provirus was inserted in the first intron of the DARS gene (chro-
mosome 2) (Fig 5B and Supplementary Table S2) that codes for a
sub-unit of a metabolic enzyme (Taft et al, 2013). We thus deter-
mined by RT–PCR that the level of DARS expression was unchanged
in the corrected stem cell compared to uninfected cells (Fig 5C). We
also used NGS data to gain information on insertion/deletion (indel)
and single nucleotide polymorphism (SNP) identified in the DARS
sequence of clone 6. None of the annotated indel or SNP was associ-
ated with disorders described in the genomic database (GWAS cata-
logue and Cosmic GS5). However, two undescribed indels and one
SNP were identified (Fig 5D). The SNP at position chr2:136673894
hits exon 11 with no consequence as the new codon coded for the
same amino acid (synonymous SNP).
Next, we investigated the transduced stem cells for immortalisa-
tion, neoplastic transformation and dissemination. First, the level
of several proteins associated with immortalisation (Hanahan &
Weinberg, 2011) was determined (Fig 6A). Levels of p16, p21, p53
and RAS (Fig 6A upper panel) and the phosphorylation of pRb
(Fig 6A lower panel) were similar in corrected stem cells (clone 6)
and in uninfected cells (RDEB) compared to squamous cell carcinoma
cell line (SCC-13). These results demonstrated that corrected stem
cells did not acquire excessive proliferative potential and did not
evade growth suppression, further supporting the results of the serial
transfer (Fig 4A) demonstrating that the cells had a finite lifespan.
Likewise, karyotype analysis demonstrated diploidy and absence of
chromosomal translocation in clone 6 and clone 22 in early and late
passages (Fig 6B). Telomere measurement by quantitative PCR
(Cawthon, 2002) did not show significant difference between clone 6
and RDEB keratinocytes at passage XIV (mass culture) (Supplemen-
tary Fig S7). Clones 6, 22 (COLVII positive) and 54 (COLVII negative)
were then subcutaneously injected into immunodeficient athymic
mice to evaluate their tumorigenic potency. None of the clones formed
tumours when compared to a squamous cell carcinoma cell line (SCC-
13), which formed sizeable tumours 2 months after injection (Fig 6C).
To test for the disseminative potential of the genetically corrected
keratinocytes, blood, gonads and other internal organs of the mice
successfully transplanted with clone 6, clone 22 or non-diseased stem
cells (YF29) were harvested and submitted to PCR analysis for human
COL7A1-specific sequences. All tests were negative (Fig 6D).
Collectively, these experiments demonstrate that it is possible to iden-
tify and expand transduced stem cells which progeny fulfil strict safety
requirements to a level of confidence never reached before.
Discussion
The strategy described here aims at narrowing the risk associated with
ex vivo gene therapy as the medicinal product is thoroughly character-
ised before its use in the clinic. The validation process meets all safety
recommendations of the International Society for Stem Cell Research
(ISSCR) and the scientific community (Taylor et al, 2010; Goldring
et al, 2011; Daley, 2012; Scadden & Srivastava, 2012). Hence, this
strategy should help regulatory agencies in their task encouraging
innovation while protecting patients (Buchholz et al, 2012; Abbott,
2013; Bianco et al, 2013a,b; Gaspar et al, 2013). Importantly, a success-
ful clonal strategy necessitates the combination of efficient transduction,
a superior culture system to efficiently expand the founder stem cells
and a performant transplantation procedure. Our experiments make this
clear demonstration using skin and validate a clonal strategy as the best
option for safe ex vivo gene therapy by today standards.
The risk of insertional mutagenesis and oncogenesis (Moiani
et al, 2012; Trono, 2012), whether the medicinal cells are adult
stem cells (Hacein-Bey-Abina et al, 2002; Mavilio et al, 2006;
Barrandon, 2007) or ES-iPS-derived cells (Hockemeyer et al, 2009),
is a major concern in ex vivo gene therapy. In fact, the use of
epidermal cells derived from genetically autologous-corrected iPS
for treating RDEB patients has been recently proposed (Itoh et al,
2011) but this strategy still relies on the use of recombinant viral
vectors to deliver the medicinal gene. Consequently, it does not
alleviate the risk of insertional mutagenesis and the need for a
clonal strategy. The fact that rearrangements of the COL7A1
transgene can be identified in clones, and not in the mass culture
from which the clones had been isolated, clearly demonstrates that
a clonal strategy brings a higher degree of sensitivity and therefore
safety. This said, it is worth-noting that rearrangements are not
necessarily deleterious as clone 6 produced perfectly functional
COLVII that, for months, participates in the formation of anchoring
fibrils. The determination of the karyotype, tumorigenicity, proviral
integrations and potential rearrangements before the cells are trans-
planted onto the patient confers additional levels of safety. Only a
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clonal strategy permits the transplantation of a safe population of
transduced cells, an otherwise impossible task with a mass culture.
Combining new generations of SIN retroviral or lentiviral shuttle
vectors with a clonal strategy (Almarza et al, 2011) is certainly the
most efficient way to minimise the risk of insertional oncogenesis
(Hacein-Bey-Abina et al, 2008; Howe et al, 2008). A clonal strategy
can also be combined with zinc finger nucleases and integrase-
defective lentiviral vectors (Lombardo et al, 2007; Genovese et al,
2014), site-specific integration and tailoring of cassette design for
sustainable gene transfer (Lombardo et al, 2011), TALE nucleases
(Hockemeyer et al, 2011; Reyon et al, 2012) or vectors with an
adaptive safety that permits the selective destruction of unwanted
recombinant cells (Di Stasi et al, 2011).
Efficacy of a medicinal stem cell product depends on permanent
stem cell engraftment, the capacity of the engrafted stem cells to
self-renew and to robustly produce the protein of interest. We have
demonstrated that it is feasible to obtain an efficacious medicinal
product from a single human epidermal stem cell, whose progeny
generates a functional epidermis that (i) self-renews for more than a
year when transplanted onto immunodeficient mice and (ii) robustly
produces the medicinal protein which incorporates into anchoring
fibrils. Consequently, the recombinant epidermis is firmly attached
onto the dermis and does not blister. Nevertheless, there are
important points that need to be emphasised. Maintenance of stem-
ness is critical and can only be achieved by minimising cell stress
during the entire ex vivo procedure. It is well known that cultured
epidermal stem cells respond to stress by undergoing clonal conver-
sion, that is converting a stem cell into a transient amplifying cell of
restricted growth potential (Barrandon et al, 2012; Rochat et al,
2013); consequently, culture exhaustion rapidly occurs, jeopardising
the production of transplantable medicinal cells and engraftment.
To limit cell stress, one must first use state-of-the-art culture condi-
tions to maintain the number of cell divisions to a minimum to
reduce telomere shortening and culture aging. We calculated
C D
A
B
Figure 5. Characterisation of proviral integrations in corrected stem cells.
A Visualisation of COL7A1 sequence by FISH analysis in corrected stem cells at passage XII (clone 6). Five specific signals (red) were detected on five different
chromosomes. As expected, a COL7A1 probe (red) hybridised to the two endogenous COL7A1 alleles located on the chromosomes 3 as identified by a specific
centromeric probe (Cen 3) and to three other chromosomes identified as chromosomes 2, 11 and 22 by means of specific centromeric probes (Cen 2, Cen 11 and
Cen 22, respectively). The latter corresponded to proviruses.
B Determination of proviral integration sites in corrected stem cell. Genomic DNA from clone 6 was submitted to whole-genome sequencing together with PCR and
subsequent Sanger sequencing to identify the integration sites to the base-pair level. Mate pairs that span from the viral sequence to a human chromosome were
extracted and used to estimate integration regions. The reads were mapped to the hg19 reference sequence. Three integration sites were uncovered: one in
chromosome 2, one in chromosome 11 and one in chromosome 22, and targeted genes were identified.
C Analysis of the level of expression of targeted genes in corrected stem cells by quantitative RT–PCR. DARS was not significantly changed in clone 6 compared to the
cells before transduction. Primers used annealed downstream of the proviral integration site. Error bars represent the standard deviation of three replicates.
D Identification of sequence abnormalities in the two alleles of the DARS-targeted gene in clone 6 by NGS. Reads were mapped to the hg19 reference sequence. Small
insertion–deletions and SNP calling were performed and compared to GWAS databases. The mapping highlighted two indels and one SNP in the DARS genomic
sequence. The indels were not associated with disease and the SNP was synonymous (CCU–CCG both codons correspond to proline).
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that the entire procedure from initial isolation of a population of
epidermal stem cells from the biopsy to the transplantation of
cloned genetically corrected CEA necessitates a maximum of 30 divi-
sions. This is a reasonable number when a holoclone can undergo
at least 180 doublings in culture (Rochat et al, 1994; Mathor et al,
1996). Second, one must favour a friendly cell-sorting technology
over fluorescence-activated cell sorting (FACS) as it is well docu-
mented that the FACS procedure is a source of stress for epidermal
stem cells (Barrandon et al, 2012). By combining a gentle manual
cloning strategy with the selection of small cells (Barrandon &
Green, 1985), we regularly achieve cloning efficiency of at least
50%, often producing more clones than one can reasonably analyse.
This said, the generation of a large number of clones can undoubt-
edly increase the chance of obtaining one or several transduced
stem cells that meet the selection criteria. For this purpose, we are
developing a high-throughput system that combines the gentle isola-
tion of numerous single cells together with an efficient identification
of clones secreting the protein of interest. The capacity to prepare
C
D
A B
Figure 6. Assessment of immortalisation, tumorigenicity and disseminative potential of the corrected stem cells.
A Upper panel: expression of proteins associated with the acquisition of immortalisation process involved in senescence, in evasion of growth suppression and in
apoptosis (Hanahan & Weinberg, 2011). The level of P53, P21, RAS and P16 was similar in clone 6, untransduced cells and mass culture from four independent
infections, significantly different from the squamous cell carcinoma cell line SCC-13. Lower panel: the phosphorylation state of the PRB restriction point was
maintained in clone 6 and untransduced recessive dystrophic epidermolysis bullosa (RDEB) cells, whereas PRB was heavily phosphorylated in transformed cells
(SCC-13). Appropriate loading controls were used for each cellular extract (GAPDH for cytoplasmic extracts, histone H3 for nuclear extracts and tubulin for whole-cell
extracts. H3 for histone H3, ppRB for hyperphosphorylated pRB and pRB for hypophosphorylated PRB).
B Transduced clone 6 had a diploid karyotype at passage XVI (see also Fig 5A).
C Transduced clones were not tumorigenic. The tumorigenic potential of the clones was tested by tumour formation in nude mice. Transduced RDEB holoclones (blue)
[clone 6 (square, n = 4) passage X, clone 22 (circle, n = 2) passage XI, clone 54 (cross, n = 4) passage X] were not tumorigenic when injected subcutaneously in athymic
mice as were untransduced RDEB keratinocytes (passage VII). SCC-13, a squamous cell carcinoma cell line (black) (lozenge, n = 2), was used as a positive control.
D To test whether the transduced RDEB keratinocytes had disseminated after the generation of an epidermis onto SCID mice (see Fig 4C), the internal organs of the
recipient mice (3 mice for clone 6 and 2 mice for clone 22) were harvested 385 days post-transplantation and analysed for COL7A1 proviral sequences. No COL7A1
sequence was detected. A mouse transplanted with a holoclone obtained from a healthy donor (YF29) was used as an internal control. PCR-positive controls were
genomic DNA from transduced cells (holoclone 6) and cDNAs isolated from healthy keratinocytes. B-actin was run as a loading control.
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transplants from a pool of fully characterised recombinant human
stem cells shall also address the question of stem cell renewal and
clonal dominance in human epidermis.
In conclusion, our experiments demonstrate for the first time the
feasibility of a clonal strategy for ex vivo gene therapy. State-of-the-
art transduction and culture technologies together with master and
working cell banks should ensure the quality and the reproducibility
of the medicinal cells (Scadden & Srivastava, 2012). Most impor-
tantly, implementing a safer procedure that reduces the odds of seri-
ous deleterious events should help the decision-making process to
perform ex vivo gene therapy (Cavazzana-Calvo et al, 2004; Mavilio,
2012); this is particularly important in the case of transplanting
young children, as is the goal in RDEB.
Materials and Methods
Cell culture
Human keratinocytes or fibroblasts were isolated from the biopsy of
the wrist of a 4-year-old RDEB patient (Hilal et al, 1993), from the
foreskin of a newborn (YF29) and from a 42-year-old female
(OR-CA) as described in the Supplementary Materials and Methods.
Studies were performed from frozen cells isolated from a biopsy
obtained with informed consent; informed consent was obtained
from patient for publication of the current study. The experiments
conformed to the principles set out in the WMA Declaration of
Helsinki and the Department of Health and Human Services
Belmont Report. Keratinocytes and the squamous cell carcinoma cell
line SCC-13 (Rheinwald & Beckett, 1981) were cultured onto a
feeder layer of lethally irradiated 3T3-J2 cells (Rheinwald & Green,
1975) in medium supplemented as described (Rochat et al, 1994;
Ronfard et al, 2000). RDEB fibroblasts were cultured in DMEM
supplemented with 10% foetal calf serum (FCS) (Hyclone). The
Flp293A-E1aColVII1 was cultured in DMEM supplemented with
10% heat-inactivated FCS. All cultures were incubated at 37°C in a
10% CO2 atmosphere.
Clonal analysis and serial transfer
Single cells were isolated as described (Barrandon & Green, 1985).
Briefly, 150 individual cells trypsinised from a mass of infected cells
were aspirated into a Pasteur pipette under a Zeiss Axiovert inverted
microscope using a 10× objective and immediately inoculated into a
35-mm size Petri dish already containing lethally irradiated 3T3-J2
cells. Clonal types were determined as described (Barrandon &
Green, 1987). CFE and serial transfer were performed as described
(Rochat et al, 1994) in the Supplementary Materials and Methods.
Vector production and retroviral infection
The Flp293A-EIaColVII1 producer clone was generated by Gene-
thon, Evry, France, as described (Schucht et al, 2006). Infection was
performed as described in the Supplementary Materials and Meth-
ods. Briefly, 2 × 104 keratinocytes from early passage were seeded
onto the 3T3-J2. Infection was performed 16–24 h later with a theo-
retical multiplicity of infection (MOI) of 10. The infection process
was repeated 24 h after the first round.
Transplantation of cultured epithelium
A fibrin-based matrix containing RDEB fibroblasts was prepared as
described (Larcher et al, 2007). A total of 105 keratinocytes were
then seeded on top of the fibrin gel, grown to confluence in culture
medium supplemented with 150 IU/ml aprotinin (Trasylol, Bayer)
and transplanted onto the back of 8- to 10-week-old Fox-Chase SCID
mice (Charles River Laboratories) following the protocol detailed in
the Supplementary Materials and Methods. Animal work was
authorised by the veterinarian canton de Vaud authorization 2033.
Animals were handled according to ethical standards by qualified
persons. Immunodeficient mice (SCID and athymic) were housed in
an official animal facility, in compliance with Swiss governmental
guidelines. Studies were monitored using an online organisational
tool. Grafts were harvested at different time points and processed
for histology, immunocytochemistry or electron microscopy. All
experiments performed conform to NIH, MRC and ARRIVAL guide-
lines for animal welfare.
Immunodetection and histology
Immunostainings were performed following standard protocols
(antibodies listed in the Supplementary Materials and Methods).
Images of sections from skin biopsies were false-coloured in green
(AF568) and red (Hoechst). Histological analyses were performed in
parallel to immunostaining.
Electron microscopy
EM was performed according to standard protocols detailed in the
Supplementary Materials and Methods. Sections were examined
with a Phillips CM10 transmission electron microscope at a filament
voltage of 80 kV. Images were collected using a CCD camera (Morada,
SIS). For immuno-electron microscopy, punches were fixed and
vibratome (Leica VT100) sectioned into 50 lm slices, cryoprotected
and freeze-thawed twice in liquid nitrogen. Immunodetection was
performed as described in the Supplementary Materials and Meth-
ods.
Western blotting
Immunoblots were performed on concentrated cell supernatants and
cell extracts as described in the Supplementary Materials and
Methods. Antibodies are listed in the Supplementary Materials and
Methods.
Karyotype and fluorescence in situ hybridisation
Karyotypes were made by ChromBios, Germany. FISH was
performed as previously described (Pinkel et al, 1988) using a
COL7A1 cDNA probe labelled with Spectrum Red as described in
the Supplementary Materials and Methods.
Tumorigenic and dissemination assays
A total of 106 transduced keratinocytes or SCC-13 cells were inocu-
lated subcutaneously into the ventral flanks of 7- to 9-week-old
athymic Swiss Nu/ mice (Charles Rivers Laboratories) with a
ª 2015 The Authors EMBO Molecular Medicine Vol 7 | No 4 | 2015
Stéphanie Droz-Georget Lathion et al Single stem cell for safe gene therapy EMBO Molecular Medicine
389
Published online: February 27, 2015 
21-gauge needle. Tumour formation was monitored twice a week
and their diameter measured. For dissemination experiments, inter-
nal organs of immunodeficient Fox-Chase SCID mice (Charles River
Laboratories) transplanted with recombinant COLVII keratinocytes
were harvested at the termination of the experiment. DNA was
extracted using the QIAamp DNA mini kit (Qiagen) according to the
manufacturer’s instructions. One hundred nanograms of DNA was
submitted to PCR (BioConcept) amplification with GoTaq PCR
reagent kit (Promega) with primers listed in the Supplementary
Materials and Methods. PCR products were sequenced (Fasteris,
Switzerland).
Quantitative reverse-transcriptase PCR
Cells were lysed in TRIzol (Invitrogen) and RNA extracted using
the RNA extraction kit (Qiagen) according to the manufacturer’s
instructions. Total cDNAs were obtained as previously described
(Bonfanti et al, 2010), and quantitative PCRs were performed with
Light-Cycler FastStart DNA Master SYBR Green I kit (Roche Diag-
nostics) in capillaries according to the manufacturer’s instructions.
Primers and programmes are listed in the Supplementary Materials
and Methods. All PCR products were sequenced (Fasteris, Switzer-
land).
Southern blotting
Genomic DNA was extracted with QiAmp DNA kit (Qiagen)
according to the manufacturer’s instructions. Ten micrograms of
DNA was codigested with SpeI/EcoRV HF (New England Biolabs)
and loaded on a 0.8% agarose (Promega) gel. After treatment
described in the Supplementary Materials and Methods, DNA was
transferred onto a Hybond XL (GE Healthcare Amersham)
membrane by capillarity and fixed with UV (Stratalinker, Strata-
gene). The membrane was then hybridised with a radiolabelled
probe as described in the Supplementary Materials and Methods.
The probe was obtained from PCR amplification of pTOPOCOL7A1
with primers described in the Supplementary Materials and Meth-
ods.
Whole-genome sequencing
Whole-genome sequencing was performed by Microsynth, Switzer-
land. Raw data are accessible on http://ncbi.nlm.nih.gov/sra/
accession number SRP050326. Briefly, 3 lg genomic DNA from
clone 6 was sequenced using SOLiD 5500xl (Life Technologies)
mate-pair reads. The reads were mapped to the hg19 reference
sequence and to the vector reference sequence from the viral
producer clone Flp293A-E1aColVII1. Mate pairs that span from the
viral sequence to a human chromosome were extracted. Specific
primers for the predicted integration sites were designed, and ampli-
fied products were sequenced to resolve the proviral integration
sites at the base-pair level. Based on the mapping, SNP calling was
performed and SNP were compared to dbSNP. Mapping, SNP and
small indel calling were performed using LifeScope 2.5.1 with stan-
dard parameters. Mapping was viewed with UCSC Genome
Browser.
A Bam file containing the hg19 mapping of the whole-genome
sequencing of clone 6 can be downloaded from http://biorepo.
epfl.ch/biorepo/public/public_link?sha1=3da4be0675e2a56b6d794
b51e82ecad821891b6a.
A bed file suitable for displaying the bam file and the insertions
sites on the UCSC genome browser is available at http://biorepo.
epfl.ch/biorepo/public/public_link?m_id=6603&sha1=b67c31d63d
2f265e905f4e3b7048595f946d80e3.
For more information
ORPHANET: http://www.orpha.net/consor/cgi-bin/index.php;
DEBRA: http://www.debra-international.org/homepage.html;
ISSCR: http://www.isscr.org/;
Fondation enfants papillons: http://www.enfants-papillons.ch/.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
The paper explained
Problem
Decision to embark in a gene therapy trial balances risk and benefit.
Despite indisputable success of several gene therapy clinical trials
using stem cells genetically corrected ex vivo, serious complications
happened with some resulting in patients’ death. These complications
resulted from insertional mutagenesis and clonal dominance that led
to irreversible cellular transformation. Much effort has been made to
design safe viral vectors and non-viral strategies. Although the most
recent technologies offer powerful tools to identify thousands of
proviral integration sites in engrafted cells, nobody has ever fully
characterised transduced medicinal cells before transplantation.
Results
We have designed a strategy to assess the safety of ex vivo gene ther-
apy before autologous transduced cells are transplanted onto the
patient. We took advantage of our extensive experience in clonal
analysis and in the cultivation of autologous epidermal cells suitable
for long-term regeneration of epidermis to treat extensive third-
degree burn wounds. Our single stem cell strategy provides a clonal
progeny large enough to thoroughly assess stemness and safety using
an array of cell and molecular assays, and to produce enough trans-
plantable autologous epidermal stem cells to treat large areas of
diseased skin. As a proof of concept, we choose recessive dystrophic
epidermolysis bullosa (RDEB), a horrendous hereditary blistering skin
disease linked to the absence of type VII collagen, a protein that
participates in the anchoring of epidermis to dermis through the
formation of anchoring fibrils. We infected RDEB keratinocytes with a
self-inactivating retroviral vector bearing a COL7A1 cDNA and cloned
the infected cells using a cell-friendly method compatible with the
maintenance of stem cell properties. Each clone of transduced RDEB
epidermal stem cells was individually expanded and characterised on
stringent criteria linked to stemness (long-term renewal, long-term
regeneration of epidermis, long-term production of the medicinal
protein COLVII, long-term reconstitution of anchoring fibrils) and
safety (immortalisation, neoplastic transformation and dissemination,
karyotype, precise determination of proviral integrations, whole-
genome sequencing). Our results demonstrate that only few
transduced cells meet stringent stemness and safety criteria, while
the vast majority of cells do not.
Impact
We demonstrate that a clonal strategy brings a level of safety that
cannot be obtained otherwise in ex vivo gene therapy. It also makes
it possible to envision exciting gene-editing technologies.
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